- Home
- HYLN vs ITOS Comparison
HYLN vs ITOS Comparison
Compare HYLN & ITOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HYLN
- ITOS
- Stock Information
- Founded
- HYLN 2018
- ITOS 2011
- Country
- HYLN United States
- ITOS United States
- Employees
- HYLN N/A
- ITOS N/A
- Industry
- HYLN Construction/Ag Equipment/Trucks
- ITOS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- HYLN Consumer Discretionary
- ITOS Health Care
- Exchange
- HYLN Nasdaq
- ITOS Nasdaq
- Market Cap
- HYLN 414.9M
- ITOS 342.6M
- IPO Year
- HYLN N/A
- ITOS 2020
- Fundamental
- Price
- HYLN $3.84
- ITOS $8.32
- Analyst Decision
- HYLN Hold
- ITOS Strong Buy
- Analyst Count
- HYLN 1
- ITOS 3
- Target Price
- HYLN $2.00
- ITOS $33.67
- AVG Volume (30 Days)
- HYLN 1.5M
- ITOS 543.4K
- Earning Date
- HYLN 11-19-2024
- ITOS 11-12-2024
- Dividend Yield
- HYLN N/A
- ITOS N/A
- EPS Growth
- HYLN N/A
- ITOS N/A
- EPS
- HYLN N/A
- ITOS N/A
- Revenue
- HYLN $96,000.00
- ITOS $35,000,000.00
- Revenue This Year
- HYLN N/A
- ITOS $271.18
- Revenue Next Year
- HYLN N/A
- ITOS N/A
- P/E Ratio
- HYLN N/A
- ITOS N/A
- Revenue Growth
- HYLN N/A
- ITOS N/A
- 52 Week Low
- HYLN $0.55
- ITOS $7.54
- 52 Week High
- HYLN $4.04
- ITOS $18.75
- Technical
- Relative Strength Index (RSI)
- HYLN 74.35
- ITOS 39.51
- Support Level
- HYLN $2.49
- ITOS $7.54
- Resistance Level
- HYLN $3.14
- ITOS $8.38
- Average True Range (ATR)
- HYLN 0.30
- ITOS 0.53
- MACD
- HYLN 0.11
- ITOS 0.01
- Stochastic Oscillator
- HYLN 88.55
- ITOS 35.94
About HYLN Hyliion Holdings Corp.
Hyliion Holdings Corp provides solutions that enable clean, flexible, and affordable electricity production. The Company focuses on delivering distributed power generators that can operate on various fuel sources to future-proof against an ever-changing energy economy. It is initially targeting the commercial and waste management industries with a locally deployable generator that can offer prime power as well as energy arbitrage opportunities. In addition to stationary power solutions, it is also focused on mobile applications, including vehicles and marine technologies. The Company aims to offer innovative, yet practical solutions that contribute positively to the environment in the energy economy.
About ITOS iTeos Therapeutics Inc.
ITeos Therapeutics Inc is a biopharmaceutical company. It designs novel product candidates with optimized pharmacologic properties to improve clinical outcomes by restoring the immune response against cancer. The company's product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist, EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody among other drug candidates.